"We are committed to creating the future of oncology by developing innovative therapies inducing autophagy to address unmet medical needs"
AbilityPharma
ABOUT
"We are committed to creating the future of oncology by developing innovative therapies inducing autophagy to address unmet medical needs"
AbilityPharma
LATEST NEWS
Press Release
Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + infoPress Release
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + infoPress Release
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + infoPress Release
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + infoPress Release
AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812 + infoPress Release
Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer + infoPress Release
AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona + infoPress Release
AbilityPharma Will Attend the ESMO Gynaecological Cancers Congress 2022 in Valencia + info
Carretera antiga Amer nº 10
17007 • Girona
E. info@neorgsite.com
http://www.neorgsite.com